Le Lézard
Classified in: Health
Subjects: CCA, FVT

Provention Bio to Report Second Quarter 2020 Financial Results and Host Conference Call on Thursday, August 6, 2020


OLDWICK, N.J., July 30, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its second quarter 2020 financial results on Thursday, August 6, 2020.

In connection with the earnings release, Provention's management team will host a live conference call and webcast at 8:00 AM ET on Thursday, August 6, 2020, to discuss the Company's financial results and provide a business update.

Conference Call Information
To access the call, please dial 1-888-567-1603 (domestic) or 1-862-298-0702 (international) five minutes prior to the start time and ask to be connected to the "Provention Bio Call." An audio webcast will also be available on the "Events and Webcasts" page of the Investors section of the Company's website, www.proventionbio.com.  An archived webcast will be available on the Company's website approximately two hours after the conference call and will be available for seven days following the call. 

About Provention Bio, Inc.
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company leveraging a transformational drug development strategy focused on the prevention or interception of immune-mediated disease. Provention's mission is to source, transform and develop therapeutic candidates targeting the high morbidity, mortality and escalating costs of autoimmune diseases. Provention's diversified portfolio includes teplizumab, a pre-commercial-stage candidate that has been shown to delay the onset of insulin-dependent type 1 diabetes (T1D) in at-risk patients during the presymptomatic phase of the disease. The Company's portfolio includes additional clinical product development candidates that have demonstrated proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus.

Investors:
Sam Martin, Argot Partners
[email protected]   
212-600-1902

Media:
Lori Rosen, LDR Communications
[email protected] 
917-553-6808

SOURCE Provention Bio, Inc.


These press releases may also interest you

at 11:34
At the Annual General Meeting of Vitrolife AB today, the following, amongst other things, was decided: Resolution in accordance with the Board's proposed dividend of SEK 1.00 per share for the financial year 2023. 29 April, 2024 was adopted as the...

at 11:25
TimelyCare, higher education's most trusted virtual health and well-being provider, has earned recognition as one of the World's Best Digital Health Companies by Newsweek, and has been awarded five Top Workplaces Awards for culture excellence....

at 11:16
Avanos Medical, Inc. will webcast its conference call discussing financial results and business highlights for the first quarter 2024 on Thursday, May 2 at 9 a.m., ET. The company will issue a news release detailing its results before the market...

at 11:15
Beijing Avistone Biotechnology Co., Ltd. (also referred to as Avistone Biotechnology or Avistone), an innovative biotechnology company focused on precision oncology therapeutics, announced the approval to expand the use of vebreltinib (also referred...

at 11:10
Through its 2030 Strategic Plan, NJII plans to double the size of the organization and to exceed $70M revenue as it rolls out various new initiatives focused on accelerating technology translation, spurring innovation and upskilling workers. As...

at 11:09
ScreenPoint Medical, today announced a significant transition in its leadership as Mark Koeniguer, the current CEO, steps down from his position. Mark served as CEO since 2022 and was instrumental in ScreenPoint's commercial growth and success over...



News published on and distributed by: